RT Book, Section
A1 NGUYEN, TIMOTHY
A1 LAPSIA, VIJAY
A1 KIM, SARA S.
A2 Cohen, Henry
SR Print(0)
ID 1112259973
T1 Erythropoietin-Stimulating Agents
T2 Casebook in Clinical Pharmacokinetics and Drug Dosing
YR 2015
FD 2015
PB McGraw-Hill Education
PP New York, NY
SN 9780071628358
LK accesspharmacy.mhmedical.com/content.aspx?aid=1112259973
RD 2024/04/19
AB Erythropoietic  stimulating  agents  (ESA)  are  recombinant  and  synthetic  erythropoietin  (EPO).  They  are  structurally  and  biologically  similar  to  endogenous  EPO  and  are  used  in  the  management  of  various  types  of  anemia.  Drugs  in  this  class  are  epoetin  alfa,  darbepoetin  alfa,  and  peginesatide.  ESAs  work  by  stimulating  the  bone  marrow  to  produce  red  blood  cells.  Epoetin  alfa,  sometimes  referred  to  as  recombinant  human  erythropoietin  (rHuEPO),  is  an  exogenous  EPO  manufactured  by  recombinant  DNA  technology,  and  it  was  approved  by  the  Food  and  Drug  Administration  (FDA)  in  1989.  It  contains  a  165-amino  acid  sequence  with  three  N-linked  and  one  O-linked  carbohydrate  changes  and  has  the  same  biological  effects  as  endogenous  EPO.1,2  It  has  a  molecular  weight  of  30,400  daltons  and  is  produced  by  mammalian  cells.